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Abstract 
Mass spectrometry has been applied to determine the deamidation sites and the 
aggregation region of the deamidated human islet amyloid polypeptide (hIAPP).  
Mutant hIAPP with iso-aspartic residue mutations at possible deamidation sites 
showed very different fibril formation behavior, which correlates with the observed 
deamidation-induced acceleration of hIAPP aggregation. 
 
 
Deamidation is a non-enzymatic post-translational modification (PTM) which 
contributes to protein ageing.1  Deamidation occurs spontaneously in solution at 
asparagine (Asn) and glutamine (Gln) residues, and results in formation of 
iso-aspartic acid/aspartic acid and γ-glutamic acid/glutamic acid (and their 
stereoisomers), respectively.2, 3  The deamidation rate of Asn is faster than Gln due to 
the shorter distance between the main chain amido group (-NH-) and the side chain 
amide group (-NH2-).4, 5  With an additional methylene group (-CH2-) into the 
backbone of iso-aspartic acid and γ-glutamic acid; the tertiary structure, stability, 
folding, and function of proteins can be dramatically altered by deamidation.6, 7  
Previous studies showed that deamidation can accelerate fibril formation in certain 
cases, including mutated amyloid-β (D7N and D23N) observed in Alzheimer’s 
disease.8, 9  Aggregation of β2-microglobulin from dialysis-associated amyloidosis 
disease,10, 11 and αB-crystallin from human eye lens have also been shown to be 
affected by deamidation.12, 13 
 Human islet amyloid polypeptide (hIAPP; also referred to as amylin) is a 
37-residue hormone peptide co-secreted with insulin and involved in regulating blood 
glucose levels.14  The concentration of hIAPP is around 1-2% relative to the level of 
insulin in secretory granules.15  hIAPP contains an intramolecular disulfide bond 
between Cys-2 and Cys-7, as well as an amidated C-terminus,16 and is an intrinsically 
disordered protein with a low level of persistent helical structure between residues 
Asn-3 and Leu-27 in solution.17  hIAPP is an amyloid protein which contains six Asn 
and one Gln as potential deamidation sites.  A previous study from Nilsson et al. 
used a variant of hIAPP segment, residues 20-29 (SNNFPAILSS) which is 
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non-amyloidogenic and showed that addition of less than 5% of deamidated monomer 
could accelerate the amyloid fibril formation.18  Results from Dunkelberger et al. 
also showed that deamidation of hIAPP disrupted the β-sheet structure around Leu-27, 
resulting in a morphology change of hIAPP fibrils, along with accelerated fibril 
formation.19  The formation of hIAPP fibrils does not contribute to type II diabetes 
(T2D); however early oligomers of hIAPP lead to the decline of pancreatic β-cell 
mass and the failure of islet cell transplantation for T2D treatment.20-22  Thus, 
accelerating the formation of the early oligomers of hIAPP may reduce the graft 
survival rate.17, 23  Deamidation has a significant impact on hIAPP fibril formation,24, 
25 the effects on the deamidation rate, the deamidation site(s), and the effects of 
isomeric deamidation products of hIAPP, however, have not yet been fully addressed. 
 MS is a powerful tool for examining deamidation in proteins as the deamidation 
reaction produces products with a mass shift of +0.984 Da (-NH2 to -OH) at the 
deamidated residue, which is readily detected by MS.26-28  Previous studies also 
suggested that deamidation can be directly quantified by measuring the peak area of 
the non-deamidated and deamidated peaks, thus the percentage of deamidation in the 
sample can be estimated.29, 30  Tandem MS/MS can further locate the deamidation 
site in proteins, and differentiate the isomeric deamidation products.2, 26-30  
Collisionally activated dissociation (CAD) MS/MS can localise deamidation site via a 
mass shift (+0.984 Da) appears in b and y ion fragments containing the deamidated 
residue, while unmodified fragments are observed in the regions not containing 
deamidated residues.30  Electron capture dissociation (ECD) MS/MS can be used to 
not only localises the deamidation site in protein, but also uses to differentiate the 
isomeric products of deamidation by the mass shift of +58 and -57 Da at the c and z 
ion fragments of iso-/γ- deamidation products respectively.  The peak intensity of 
iso-/γ- deamidation products can also compare with the peak intensity of aspartic 
acid/glutamic acid in order to determine the ratio of the isomeric products.29 
 In order to localise the deamidation site(s) in the incubated hIAPP solution, CAD 
MS/MS with a 12 Tesla (T) Fourier transform ion cyclotron mass spectrometer 
(FTICR MS) was applied.  The y5 fragment clearly showed a deamidated peak in the 
incubated sample (Fig. 1B), indicating deamidation occurs at Asn-35 residue in hIAPP.  
For the b fragments, no deamidated peaks were observed for the first 20 amino acid 
residues (Fig. 1C); however, a deamidated peak was present corresponding to the b21 
fragment (Fig. 1D), suggesting deamidation only occurs at Asn-21 but not at Asn-3, 
Gln-10, and Asn-14 residues.  Furthermore, another deamidated peak was detected 
corresponding to the b22 fragment ion in the incubated solution (Fig. 1E), indicating 
Asn-22 also deamidates within four weeks at 37oC. 
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Figure 1. (A) The amino acid sequence of hIAPP. The potential deamidation sites are coloured in red. 
Key CAD MS/MS fragments of hIAPP revealing deamidation at amino acid residues after 4 weeks 
incubation at 37oC are shown (B) y5, (C) b20, (D) b21, and (E) b22. The blue/red circles indicate the 
isotopic peaks of singly/doubly deamidated fragments, respectively. 
 
 Subsequently, MS was applied to determine the deamidation rates of each 
individual deamidated site in the incubated solutions and resulting fibrils by 
calculating the percentage ratio between the non-deamidated and the deamidated 
fragment ion peak areas for each sample.  In the incubated solution, the earliest 
deamidation instance was observed on day 5, and was identified within the y5 
fragment ion (Fig. 2A), indicating the Asn-35 is the first amino acid residue in hIAPP 
to undergo deamidation, which requires 5-day of incubation at 37oC.  Deamidation at 
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the b21 and b22 fragment ions was observed on day 8, suggesting Asn-21 and Asn-22 
residues are the next amino acid residue to deamidate in hIAPP and require a longer 
incubation time for deamidation compared to Asn-35 residue.  Though the extent of 
deamidation increased with the incubation time; a similar percentage and rate of 
deamidation were found in the y5, b21, and b22 fragment ions at the various time points 
for the incubated solutions.  After 28 days incubation, each deamidated fragment ion 
(y5, b21, and b22) of the soluble hIAPP showed ~18% deamidation, indicating even 
though the initial deamidation time between Asn-21, Asn-22, and Asn-35 residues are 
different, the extent as well as the rate of deamidation of these residues are similar 
across and at the end of the incubation time.  The insoluble protein pellets formed 
over the course of the incubation were re-solubilised and showed a greater extent of 
deamidation than the soluble hIAPP species.  Deamidation was observed in the 
day-7, day-14, day-21, and day-28 samples (Fig. 2B).  On day-7, ~7.5% of the y5 
fragment ion was deamidated while no deamidation was observed for the b21 and b22 
fragment ions in the pellet.  On day-14, the extent of deamidation for the y5 fragment 
ion increased sharply to 16% and the b21 and b22 showed ~7.5% deamidation.  
After 28 days incubation, the extent of deamidation of the y5, b21, and b22 fragment 
ions were at 39%, 30%, and 29% respectively, distinctly larger than for the soluble 
hIAPP species above, suggesting the fibrils of hIAPP contains a higher extent of 
deamidation at Asn-35 compared to Asn-21 and Asn-22 residues.  The residue 
Asn-35 was the earliest deamidation site observed in the incubated solutions and 
contained the highest extent of deamidation in the fibril pellets, which agrees with the 
findings in previous deamidation studies,3, 31 suggesting that the primary sequence of 
Ser-35Asn-Thr in hIAPP had the shortest deamidation time among all the other 
segments studied.  The higher extent of deamidation observed in the fibrils of hIAPP 
compared to the incubated solutions also indicates that deamidated hIAPP tends to 
aggregate and form insoluble fibrils more rapidly than the wild-type hIAPP. 
 
Figure 2. The extent of deamidation observed in CAD MS/MS fragments; the y5 (black), b21 (red), and 
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b22 (blue) for 10 μM aqueous hIAPP (A) solutions and (B) dissolved fibril solutions. 
 In order to ascertain the effects of deamidated isomeric products on the 
aggregation process, pure mutant hIAPP peptides were synthesised with aspartic acid 
((D)3hIAPP) or iso-aspartic acid ((isoD)3hIAPP) replacement at the detected 
deamidation site from above, i.e. residues 21, 22, and 35 (Fig. S1, ESI†).  The 7+ 
charge state dimers of ((D)3hIAPP) and ((isoD)3hIAPP) were fragmented by ECD 
MS/MS in order to determine the non-covalent interaction region between the mutant 
hIAPP units (Fig. S2 – S3, ESI†).  The aggregation regions of ((D)3hIAPP) and 
((isoD)3hIAPP) were found between Asn-31 and Thr-36 residues, which is similar to 
the proposed aggregation region of 7+ charge state dimer of wild-type hIAPP in the 
previous studies, suggesting there is no difference between the wild-type and the two 
mutant hIAPPs regarding the aggregation sites for the formation of early oligomers.32   
 MS can quantify soluble amyloid proteins in solution.32  The ionisation of 
aqueous protein solutions to gas phase ions, however, is limited to soluble 
components only, so that the insoluble fibrils are difficult to quantify using MS.  
Thus, the relative concentration of amyloid fibrils formed in the incubated solutions 
were determined by using Thioflavin T (ThT) fluorescence emission analysis at the 
wavelength of 490 nm and the overall structures of fibrils were observed using 
transmission electron microscopy (TEM).  The relative fluorescence emission of the 
10 μM solutions of wild-type hIAPP, ((D)3hIAPP), and ((isoD)3hIAPP) were 
measured and the lag phases of the formation of mature fibrils in wild-type hIAPP 
solution was 42 hours while in ((D)3hIAPP) and ((isoD)3hIAPP) solutions were ~ 30 
hours (Fig. 3A – 3C), indicating mutant hIAPPs with deamidated residues 
replacement at Asn-21, Asn-22, and Asn-35 accelerate the rate of mature fibrils 
formation which supports the hypothesis that deamidated hIAPPs accelerate the 
aggregation rate of non-deamidated hIAPP.18, 19  TEM images of the wild-type hIAPP, 
((D)3hIAPP), and ((isoD)3hIAPP) solutions incubated at 37oC for one week were also 
obtained (Fig. 3E – 3G).  Branched and elongated fibrils were observed in the 
wild-type hIAPP as well as ((D)3hIAPP) incubated solutions; while densely packed 
fibrils were found in ((isoD)3hIAPP) solution.  The fibril structures observed in 
((isoD)3hIAPP) solution were distinctly different from the fibrils found in wild-type 
hIAPP and ((D)3hIAPP), suggesting the morphology of fibrils formed in 
((isoD)3hIAPP) is different from wild-type hIAPP as well as ((D)3hIAPP). 
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Figure 3.  The relative fluorescence activity of the incubated 10 μM (A) ThT solution (control; black), 
10 μM wild-type hIAPP (blue), (B) 10 μM mutant ((D)3hIAPP) (green), and (C) 10 μM mutant 
((isoD)3hIAPP) (red) solutions measured at emission 490 nm.  The TEM images of the (D) fresh and 
(E) 1-week incubated 10 μM wild-type hIAPP solutions. The TEM images of 10 μM (F) ((D)3hIAPP) 
and (G) ((isoD)3hIAPP) solutions after 1 week incubation at 37oC.  The scale bars for each TEM 
image are inset. 
 
 In order to study the effects of the isomeric deamidation products on the 
wild-type hIAPP aggregation, ((D)3hIAPP) and ((isoD)3hIAPP) solutions were 
individually spiked into wild-type hIAPP solution at 5%, 10%, 25%, and 50% 
amounts.  After one week incubation, the percentage of remaining soluble 
monomeric hIAPP in the seeded solutions was consistently less in the spiked solutions 
than the control hIAPP incubated solution, and less soluble hIAPP was found in the 
mutant ((isoD)3hIAPP) spiked solutions compared to the ((D)3hIAPP) spiked 
solutions (Fig. 4A).  The p-values of seeding 5% and 10% mutant ((D)3hIAPP) into 
the solution were higher than 0.05, which indicated the differences between the 
seeded solutions and the control sample were not significant.  The p-values of the 
remaining seeded solutions were less than 0.05, which showed significant differences 
between the control and the seeded solutions.  The normalised percentage of soluble 
hIAPP with 5% spiking of ((D)3hIAPP) or ((isoD)3hIAPP) was 4% and 9% less than 
the soluble hIAPP found in the control incubated solutions respectively.  The 
normalised percentage of soluble hIAPP consistently decreased with increased 
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amounts of ((D)3hIAPP) or ((isoD)3hIAPP) in the incubated solutions.  For the 
solutions with 50% spiking of ((D)3hIAPP) or ((isoD)3hIAPP), the normalised 
percentage of soluble hIAPP was 28% and 46% less than the soluble hIAPP found in 
the control solutions respectively.  These results indicate the effects of mutant 
hIAPPs in accelerating wild-type hIAPP are concentration-dependent. 
 
Figure 4.  (A) A plot showing the normalised percentage of soluble hIAPP in the 10 μM solutions 
with spiking different percentage of mutant ((D)3hIAPP) or ((isoD)3hIAPP) to wild-type hIAPP 
(control) measured using MS after 1 week incubation.  * indicates the p-value of the sample 
percentages are less than 0.05 compared to the control percentage in a paired t-test.  (D) The relative 
fluorescence activity of 10 μM hIAPP, 9.5 μM hIAPP plus 0.5 μM (5%) ((D)3hIAPP), and 9.5 μM 
hIAPP plus 0.5 μM (5%) ((isoD)3hIAPP) measured at emission 490 nm.   
 
 The fibrils formed during the incubation experiments were measured using ThT 
fluorescence spectroscopy.  The measured percentage change of fluorescence 
emission in 5% mutant hIAPP seeded solutions further indicated that the amount of 
amyloid fibrils formed in the seeded solutions were consistently higher than the 
wild-type hIAPP incubated solution and the overall percentage of amyloid fibrils 
formed in ((D)3hIAPP) and ((isoD)3hIAPP) seeded solutions was 27% and 48% 
higher than the wild-type hIAPP incubated solution respectively (Fig. 4B).  The 
fluorescence emission measurement and MS quantification showed the effect of 
seeding ((isoD)3hIAPP) is twice that of seeding the same amount of ((D)3hIAPP) into 
non-deamidated hIAPP solutions.  The difference between the TEM images of 
incubated ((D)3hIAPP) and ((isoD)3hIAPP) solutions also agrees the greater effect of 
((isoD)3hIAPP) compared to ((D)3hIAPP) (Fig. 3E – 3G).  The observed 
morphology of fibrils was different in ((isoD)3hIAPP) compared to ((D)3hIAPP), 
indicating differences in the aggregation behaviour and rate of non-deamidated hIAPP, 
as observed in the MS and fluorescence. 
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 In order to examine the effects of mutant ((D)3hIAPP) and ((isoD)3hIAPP) in 
incubated solutions and fibrillary pellets, MS spectra of mixed wild-type hIAPP with 
various spiking percentage of mutant ((D)3hIAPP) and ((isoD)3hIAPP) were acquired 
(Fig. S4, ESI†).  The peak intensity of mutant ((D)3hIAPP) and ((isoD)3hIAPP) were 
consistently higher in the fibrillary pellets compared to the incubated and the fresh 
solutions, suggesting the important role of ((D)3hIAPP) or ((isoD)3hIAPP) in 
enhancing fibril formation.  
 The experimental results herein demonstrate the importance as well as the effects 
of hIAPP deamidation on hIAPP aggregation rate.  Deamidation of hIAPP is shown 
to occur at Asn-21, Asn-22, as well as Asn-35 residues of the incubation and a higher 
percentage of deamidated hIAPP was observed in fibrillary pellet, suggesting that 
deamidated hIAPP can accelerate the rate of hIAPP fibril formation.  The 
experimental results of the mutant hIAPP, ((D)3hIAPP) and ((isoD)3hIAPP), not only 
agree with the hypothesis of deamidated hIAPP can increase fibril formation, but also 
suggest the effect of seeding ((isoD)3hIAPP) is twice than that of ((D)3hIAPP) seeding 
into non-deamidated hIAPP solutions as the morphology of ((isoD)3hIAPP) fibrils are 
distinctly different from the fibrils formed in ((D)3hIAPP) solutions.  These results 
provide qualitative and quantitative evaluation of deamidated hIAPP on the rate of 
aggregation which could help inform further studies of the effects of deamidation on 
accelerating amyloid fibril formation.  
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 Graphic Abstracts: 
 
Deamidation sites of hIAPP were determined and the amount of fibril formed in 
mutant hIAPPs were higher than wild-type hIAPP. 
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Electronic Supplementary Information 
Experimental Procedure 
Sample preparation for deamidated hIAPP and fibrils.  Wild-type hIAPP 
lyophilized powder (Sigma Aldrich Company Ltd, Dorset, England) was dissolved in 
Milli-Q (Direct-Q® 3 UV System, Millipore Corporation, US) H2O (~pH 7.5) at a 
concentration of 500 µM and further diluted into 10 uM solution. The 10 µM hIAPP 
aqueous solution was incubated for 28 days (4 weeks).  The incubated solution was 
then centrifuged at 14,000 rpm for one hour to separate the soluble hIAPP 
(supernatant) from the insoluble hIAPP fibril (fibrillary pellet).  The supernatant 
solution containing soluble hIAPP was then diluted 20-fold with 49.5:49.5:1 
water/acetonitrile/formic acid prior to MS analysis. hIAPP fibrillary pellets from 7-, 
14-, 21-, and 28-day solutions were rinsed with 100 μL Milli-Q H2O three times and 
then re-dissolved with 20 µL of 47.5:47.5:5 water/acetonitrile/formic acid, and 
sonicated in water bath at 37 oC for one hour.  Re-dissolved samples were further 
diluted with 80 µL of 50:50 water/acetonitrile. The final concentration of formic acid 
in solutions was 1% (mol/mol). 
 
Sample preparation for seeding mutant peptides.  Wild-type hIAPP lyophilized 
powder and synthetic mutant hIAPPs (Pepscan Company Ltd, The Netherlands) were 
dissolved in Milli-Q H2O to a concentration of 500 µM.  The seeding experiments 
were performed by mixing wild-type hIAPP stock solution with 5%, 10%, 25%, or 
50% mutant ((D)3hIAPP) or ((isoD)3hIAPP) solutions.  Samples were then diluted to 
a final concentration of 10 µM wild-type hIAPP plus mutant ((D)3hIAPP) or 
((isoD)3hIAPP), which were incubated for 1 week at 37oC.  The supernatants and 
fibrillary pellets were separated and prepared as mentioned above. 
 
FTICR MS analysis.  Mass spectra were acquired on a 12 tesla solariX FTICR MS 
(Bruker Daltonik GmbH, Bremen, Germany).  All samples were analyzed in positive 
ionization mode.  For the detection of deamidated hIAPP and dissociated fibrils, an 
Apollo II electrospray ionization (ESI) source (Bruker Daltonik GmbH, Bremen, 
Germany) was used with a capillary voltage of 4-4.5 kV.  The ESI flow rate was 
optimized to 100-150 µL/h and the source temperature was set to 200oC.  Ions were 
externally accumulated in a hexapole collision cell before transferred to an infinity 
cell (ICR cell) for excitation and detection.33  Data obtained from FTICR-MS were 
analyzed using Bruker DataAnalysis 4.2 software (Bruker Daltonics, Bremen, 
Germany).  For the CAD experiments, precursor ions were first isolated using the 
quadrupole mass filter, then collided with argon gas and accumulated in the collision 
cell.  The collision energy was optimized to 2-18 V and the ion accumulation time to 
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1-3 seconds.  Fragments were then transferred to the infinity cell for detection.  The 
most intense isotopic peak from each fragment with signal-to-noise ratio (S/N) over 5 
was manually matched with the theoretical m/z.  All of the fragments were internally 
calibrated and then assigned with an uncertainty less than 1 part-per-million (ppm). 
 
Quantification of deamidated/ mutant hIAPP in solutions and fibrillary pellets.  
The monoisotopic peak area of non-deamidated and deamidated/mutant hIAPP peaks 
were measured using Bruker DataAnalysis 4.2 software.  The percentage of 
deamidated hIAPP (%) was calculated as follows:  
Deamidated (%) = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑃𝑃𝑃𝑃 𝑜𝑜𝑜𝑜 𝑑𝑑𝑃𝑃𝑃𝑃𝑑𝑑𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑𝑃𝑃𝑑𝑑 ℎ𝐼𝐼𝐼𝐼𝑃𝑃𝑃𝑃
𝑆𝑆𝑆𝑆𝑑𝑑 𝑜𝑜𝑜𝑜 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑃𝑃𝑃𝑃 𝑜𝑜𝑜𝑜 𝑑𝑑𝑃𝑃𝑃𝑃𝑑𝑑𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑𝑃𝑃𝑑𝑑 ℎ𝐼𝐼𝐼𝐼𝑃𝑃𝑃𝑃 𝑃𝑃𝑎𝑎𝑑𝑑 𝑎𝑎𝑜𝑜𝑎𝑎𝑑𝑑𝑃𝑃𝑃𝑃𝑑𝑑𝑑𝑑𝑑𝑑𝑃𝑃𝑑𝑑𝑃𝑃𝑑𝑑 ℎ𝐼𝐼𝐼𝐼𝑃𝑃𝑃𝑃  𝑥𝑥 100% 
The same calculation method was applied to obtain the percentage of mutant hIAPP 
against wild-type hIAPP.  
 
Transmission electron microscopy (TEM).  The TEM images of the incubated 
solutions, including 10 µM wild-type hIAPP, 10 µM mutant ((D)3hIAPP), and 10 µM 
mutant ((isoD)3hIAPP) solution were acquired on a Jeol 2010F TEM operated at 200 
kV.  10 µL of incubated solution was transferred onto a carbon-coated grid and 
settled for one minute, followed by removing the excess solution using filter paper. A 
2% (w/v) uranyl acetate solution was used for the negative stain. Multiple images 
with magnification from x10,000 to x40,000 were acquired.  
 
Thioflavin T (ThT) fluorescence reactivity.  The fluorescence reactivity of the 10 
µM hIAPP, mutant ((D)3hIAPP), mutant ((isoD)3hIAPP), and hIAPP seeding 
solutions were measured using a GloMax®-Multi Detection System (Promega; 
Wisconsin, USA).  All samples were placed in a black 96 well-plate and mixed with 
10 µM ThT aqueous solution.  Fluorescence spectra of the samples were acquired 
every 45 minutes with excitation at 405 nm and emission measurement at 490 nm, in 
a similar fashion to Chan et al.34, 35  The intensities obtained from the fluorescence 
spectrometer were normalized to the signal intensity of the most mature fibril. 
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 Figure S1. Sequences of synthetic mutant hIAPPs. Asn residues at position 21, 22, 
and 35 are replaced with aspartic acid – deamidated ((D)3hIAPP) or iso-aspartic acid 
– deamidated ((isoD)3hIAPP) in order to act as deamidation mimics. 
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 Figure S2.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the (B) 
ECD MS/MS spectrum of the 7+ charge state ((D)3hIAPP) dimer.  Highlighted 
sequence represents the proposed non-covalent interaction region.  The side chain 
losses were not labeled for clarity.  The assigned fragments are listed in the ESI 
Table S1. 
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Table S1.  List of the assigned fragments from the ECD MS/MS spectrum of the 7+ 
charge state ((D)3hIAPP) dimer ion.  M represents one ((D)3hIAPP) unit. 
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Figure S3.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the (B) 
ECD MS/MS spectrum of the 7+ charge state ((isoD)3hIAPP) dimer.  Highlighted 
sequence represents the proposed non-covalent interaction region. The side chain 
losses were not labeled for clarity.  The assigned fragments are listed in the ESI 
Table S2. 
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Table S2.  List of the assigned fragments from the ECD MS/MS spectrum of the 7+ 
charge state ((isoD)3hIAPP) dimer ion.  M represents one ((isoD)3hIAPP) unit. 
  
18 
 
 Figure S4.  The nESI-MS spectra showing the fresh, the incubated solutions, and the 
incubated fibrillary pellets of hIAPP mixed with 5%, 10%, 25%, or 50% of mutant 
((D)3hIAPP) or ((isoD)3hIAPP). 
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